{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ABCG2", "SLC2A9", "bergenin", "hyperuricemia", "urate-lowering therapeutic"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "32850823", "DateRevised": {"Year": "2020", "Month": "09", "Day": "28"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "07", "Day": "29"}], "Language": ["eng"], "ELocationID": ["703", "10.3389/fcell.2020.00703"], "Journal": {"ISSN": "2296-634X", "JournalIssue": {"Volume": "8", "PubDate": {"Year": "2020"}}, "Title": "Frontiers in cell and developmental biology", "ISOAbbreviation": "Front Cell Dev Biol"}, "ArticleTitle": "Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia.", "Pagination": {"StartPage": "703", "MedlinePgn": "703"}, "Abstract": {"AbstractText": ["Bergenin is a C-glucoside of 4-<i>O</i>-methyl gallic acid isolated from several medicinal plants and has multiple biological activities. The aim of this study was to assess the potential usefulness of bergenin in hyperuricemia. We found that bergenin reduced serum urate levels in hyperuricemia mice by promoting renal and gut uric acid excretion. Bergenin treatment increased <i>Abcg2</i> expression both in the kidneys and intestine, while the expression of <i>Slc2a9</i> was suppressed in the kidney and increased in the intestine. Moreover, bergenin induced <i>ABCG2</i> expression in HK-2 and Caco-2 cells, as well as <i>SLC2A9</i> in Caco-2 cells, via the activation of <i>PPAR</i>\u03b3. Nevertheless, bergenin suppressed <i>SLC2A9</i> expression in HK-2 cells by inhibiting the nuclear translocation of p53. Furthermore, bergenin decreased the serum levels of IL-6, IL-1\u03b2, and TNF-\u03b1 in hyperuricemia mice, and promoted a polarization shift from the M1 to M2 phenotype in RAW264.7 cells. In conclusion, these findings provide evidence supporting the further development of bergenin as a novel therapeutic strategy for hyperuricemia."], "CopyrightInformation": "Copyright \u00a9 2020 Chen, Ye, Zhu, Zhang, Jiang, Lu and Wu."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Chen", "ForeName": "Mo", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Orthopedic, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Ye", "ForeName": "Chenyi", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Zhu", "ForeName": "Jianing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Zhang", "ForeName": "Peiyu", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Jiang", "ForeName": "Yujie", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Lu", "ForeName": "Xiaoyong", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China."}], "LastName": "Wu", "ForeName": "Huaxiang", "Initials": "H"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Cell Dev Biol", "NlmUniqueID": "101630250", "ISSNLinking": "2296-634X"}}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Barai P., Raval N., Acharya S., Borisa A., Bhatt H., Acharya N. (2019). Neuroprotective effects of bergenin in Alzheimer\u2019s disease: investigation through molecular docking, in vitro and in vivo studies. Behav. Brain Res. 356 18\u201340. 10.1016/j.bbr.2018.08.010", "ArticleIdList": ["10.1016/j.bbr.2018.08.010", "30118774"]}, {"Citation": "Berger J., Moller D. E. (2002). The mechanisms of action of PPARs. Annu. Rev. Med. 53 409\u2013435. 10.1146/annurev.med.53.082901.104018", "ArticleIdList": ["10.1146/annurev.med.53.082901.104018", "11818483"]}, {"Citation": "Chen M., Lu X., Lu C., Shen N., Jiang Y., Chen M., et al. (2018). Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway. Arthritis Res. Ther. 20:20. 10.1186/s13075-018-1512-4", "ArticleIdList": ["10.1186/s13075-018-1512-4", "PMC5803867", "29415757"]}, {"Citation": "Chen-Xu M., Yokose C., Rai S. K., Pillinger M. H., Choi H. K. (2019). Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National health and nutrition Examination Survey, 2007\u20132016. Arthritis Rheumatol. 71 991\u2013999. 10.1002/art.40807", "ArticleIdList": ["10.1002/art.40807", "PMC6536335", "30618180"]}, {"Citation": "Chou H. C., Wen L. L., Chang C. C., Lin C. Y., Jin L., Juan S. H. (2017). From the Cover: l-Carnitine via PPARgamma- and Sirt1-dependent mechanisms attenuates epithelial-mesenchymal transition and renal fibrosis caused by perfluorooctanesulfonate. Toxicol. Sci. 160 217\u2013229. 10.1093/toxsci/kfx183", "ArticleIdList": ["10.1093/toxsci/kfx183", "28973641"]}, {"Citation": "Crisan T. O., Cleophas M. C., Oosting M., Lemmers H., Toenhake-Dijkstra H., Netea M. G., et al. (2016). Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann. Rheum. Dis. 75 755\u2013762. 10.1136/annrheumdis-2014-206564", "ArticleIdList": ["10.1136/annrheumdis-2014-206564", "25649144"]}, {"Citation": "Cri\u015fan T. O., Cleophas M. C. P., Novakovic B., Erler K., Van De Veerdonk F. L., Stunnenberg H. G., et al. (2017). Uric acid priming in human monocytes is driven by the AKT\u2013PRAS40 autophagy pathway. Proc. Natl. Acad. Sci. U.S.A. 114 5485\u20135490. 10.1073/pnas.1620910114", "ArticleIdList": ["10.1073/pnas.1620910114", "PMC5448210", "28484006"]}, {"Citation": "Dalbeth N., Choi H. K., Joosten L. A. B., Khanna P. P., Matsuo H., Perez-Ruiz F., et al. (2019). Gout. Nat. Rev. Dis. Primers 5:69. 10.1038/s41572-019-0115-y", "ArticleIdList": ["10.1038/s41572-019-0115-y", "31558729"]}, {"Citation": "DeBosch B. J., Kluth O., Fujiwara H., Schurmann A., Moley K. (2014). Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat. Commun. 5:4642. 10.1038/ncomms5642", "ArticleIdList": ["10.1038/ncomms5642", "PMC4348061", "25100214"]}, {"Citation": "Dinour D., Gray N. K., Campbell S., Shu X., Sawyer L., Richardson W., et al. (2010). Homozygous SLC2A9 mutations cause severe renal hypouricemia. J. Am. Soc. Nephrol. 21 64\u201372. 10.1681/ASN.2009040406", "ArticleIdList": ["10.1681/ASN.2009040406", "PMC2799278", "19926891"]}, {"Citation": "Feng Y., Liu T., Dong S. Y., Guo Y. J., Jankovic J., Xu H., et al. (2015). Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. J. Neurochem. 134 668\u2013676. 10.1111/jnc.13172", "ArticleIdList": ["10.1111/jnc.13172", "25991017"]}, {"Citation": "Han L., Zhou R., Niu J., Mcnutt M. A., Wang P., Tong T. (2010). SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res. 38 7458\u20137471. 10.1093/nar/gkq609", "ArticleIdList": ["10.1093/nar/gkq609", "PMC2995042", "20660480"]}, {"Citation": "Hou W., Ye C., Chen M., Li W., Gao X., He R., et al. (2019). Bergenin activates SIRT1 as a novel therapeutic agent for osteogenesis of bone mesenchymal stem cells. Front. Pharmacol. 10:618. 10.3389/fphar.2019.00618", "ArticleIdList": ["10.3389/fphar.2019.00618", "PMC6586741", "31258473"]}, {"Citation": "Ichida K., Matsuo H., Takada T., Nakayama A., Murakami K., Shimizu T., et al. (2012). Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3:764. 10.1038/ncomms1756", "ArticleIdList": ["10.1038/ncomms1756", "PMC3337984", "22473008"]}, {"Citation": "Itahana Y., Han R., Barbier S., Lei Z., Rozen S., Itahana K. (2015). The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense. Oncogene 34 1799\u20131810. 10.1038/onc.2014.119", "ArticleIdList": ["10.1038/onc.2014.119", "24858040"]}, {"Citation": "Jain S. K., Singh S., Khajuria A., Guru S. K., Joshi P., Meena S., et al. (2014). Pyrano-isochromanones as IL-6 inhibitors: synthesis, in vitro and in vivo antiarthritic activity. J. Med. Chem. 57 7085\u20137097. 10.1021/jm500901e", "ArticleIdList": ["10.1021/jm500901e", "25111439"]}, {"Citation": "Ji Y., Wang D., Zhang B., Lu H. (2019). Bergenin ameliorates MPTP-induced Parkinson\u2019s disease by activating PI3K/Akt signaling pathway. J. Alzheimers Dis. 72 823\u2013833. 10.3233/JAD-190870", "ArticleIdList": ["10.3233/JAD-190870", "31658061"]}, {"Citation": "Joosten L. A. B., Crisan T. O., Bjornstad P., Johnson R. J. (2020). Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat. Rev. Rheumatol. 16 75\u201386. 10.1038/s41584-019-0334-3", "ArticleIdList": ["10.1038/s41584-019-0334-3", "PMC7075706", "31822862"]}, {"Citation": "Kawamura Y., Nakaoka H., Nakayama A., Okada Y., Yamamoto K., Higashino T., et al. (2019). Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. Ann. Rheum Dis. 78 1430\u20131437. 10.1136/annrheumdis-2019-215521", "ArticleIdList": ["10.1136/annrheumdis-2019-215521", "PMC6788923", "31289104"]}, {"Citation": "Kim S. M., Lee S. H., Kim Y. G., Kim S. Y., Seo J. W., Choi Y. W., et al. (2015). Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 308 F993\u2013F1003. 10.1152/ajprenal.00637.2014", "ArticleIdList": ["10.1152/ajprenal.00637.2014", "25651569"]}, {"Citation": "Kumar S., Sharma C., Kaushik S. R., Kulshreshtha A., Chaturvedi S., Nanda R. K., et al. (2019). The phytochemical bergenin as an adjunct immunotherapy for tuberculosis in mice. J. Biol. Chem. 294 8555\u20138563. 10.1074/jbc.RA119.008005", "ArticleIdList": ["10.1074/jbc.RA119.008005", "PMC6544861", "30975902"]}, {"Citation": "Kuo C. F., Grainge M. J., Zhang W., Doherty M. (2015). Global epidemiology of gout: prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11 649\u2013662. 10.1038/nrrheum.2015.91", "ArticleIdList": ["10.1038/nrrheum.2015.91", "26150127"]}, {"Citation": "Lee W., Belkhiri A., Lockhart A. C., Merchant N., Glaeser H., Harris E. I., et al. (2008). Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 68 10315\u201310323. 10.1158/0008-5472.CAN-08-1984", "ArticleIdList": ["10.1158/0008-5472.CAN-08-1984", "PMC2605661", "19074900"]}, {"Citation": "Liang C., Pei S., Ju W., Jia M., Tian D., Tang Y., et al. (2017). Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids. Eur. J. Med. Chem. 133 319\u2013328. 10.1016/j.ejmech.2017.03.053", "ArticleIdList": ["10.1016/j.ejmech.2017.03.053", "28395218"]}, {"Citation": "Lopes de Oliveira G. A., Alarc\u00f3n De La Lastra C., Rosillo M., Castejon Martinez M. L., S\u00e1nchez-Hidalgo M., Rolim Medeiros J. V., et al. (2019). Preventive effect of bergenin against the development of TNBS-induced acute colitis in rats is associated with inflammatory mediators inhibition and NLRP3/ASC inflammasome signaling pathways. Chemico Biol. Interact. 297 25\u201333. 10.1016/j.cbi.2018.10.020", "ArticleIdList": ["10.1016/j.cbi.2018.10.020", "30365937"]}, {"Citation": "Lu J., Dalbeth N., Yin H., Li C., Merriman T. R., Wei W. H. (2019). Mouse models for human hyperuricaemia: a critical review. Nat. Rev. Rheumatol. 15 413\u2013426. 10.1038/s41584-019-0222-x", "ArticleIdList": ["10.1038/s41584-019-0222-x", "31118497"]}, {"Citation": "Mandard S., Patsouris D. (2013). Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res. 2013:613864. 10.1155/2013/613864", "ArticleIdList": ["10.1155/2013/613864", "PMC3614066", "23577023"]}, {"Citation": "Mukherjee H., Ojha D., Bharitkar Y. P., Ghosh S., Mondal S., Kaity S., et al. (2013). Evaluation of the wound healing activity of Shorea robusta, an Indian ethnomedicine, and its isolated constituent(s) in topical formulation. J. Ethnopharmacol. 149 335\u2013343. 10.1016/j.jep.2013.06.045", "ArticleIdList": ["10.1016/j.jep.2013.06.045", "23838474"]}, {"Citation": "Nakamura K., Zhang M., Kageyama S., Ke B., Fujii T., Sosa R. A., et al. (2017). Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. J. Hepatol. 67 1232\u20131242. 10.1016/j.jhep.2017.08.010", "ArticleIdList": ["10.1016/j.jhep.2017.08.010", "PMC5884687", "28842295"]}, {"Citation": "Nakatochi M., Kanai M., Nakayama A., Hishida A., Kawamura Y., Ichihara S., et al. (2019). Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. Commun. Biol. 2:115. 10.1038/s42003-019-0339-0", "ArticleIdList": ["10.1038/s42003-019-0339-0", "PMC6453927", "30993211"]}, {"Citation": "Nakayama A., Nakaoka H., Yamamoto K., Sakiyama M., Shaukat A., Toyoda Y., et al. (2017). GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann. Rheum. Dis. 76 869\u2013877. 10.1136/annrheumdis-2016-209632", "ArticleIdList": ["10.1136/annrheumdis-2016-209632", "PMC5530361", "27899376"]}, {"Citation": "Perez-Ruiz F., Calabozo M., Erauskin G. G., Ruibal A., Herrero-Beites A. M. (2002). Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum. 47 610\u2013613. 10.1002/art.10792", "ArticleIdList": ["10.1002/art.10792", "12522834"]}, {"Citation": "Phay J. E., Hussain H. B., Moley J. F. (2000). Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 66 217\u2013220. 10.1006/geno.2000.6195", "ArticleIdList": ["10.1006/geno.2000.6195", "10860667"]}, {"Citation": "Roberts R. L., Wallace M. C., Phipps-Green A. J., Topless R., Drake J. M., Tan P., et al. (2017). ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 17 201\u2013203. 10.1038/tpj.2015.101", "ArticleIdList": ["10.1038/tpj.2015.101", "26810134"]}, {"Citation": "Shapouri-Moghaddam A., Mohammadian S., Vazini H., Taghadosi M., Esmaeili S. A., Mardani F., et al. (2018). Macrophage plasticity, polarization, and function in health and disease. J. Cell. Physiol. 233 6425\u20136440. 10.1002/jcp.26429", "ArticleIdList": ["10.1002/jcp.26429", "29319160"]}, {"Citation": "Singh R., Kumar V., Bharate S. S., Vishwakarma R. A. (2017). Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis. Bioorg. Med. Chem. 25 5513\u20135521. 10.1016/j.bmc.2017.08.011", "ArticleIdList": ["10.1016/j.bmc.2017.08.011", "28843845"]}, {"Citation": "Stiburkova B., Pavelcova K., Pavlikova M., Jesina P., Pavelka K. (2019). The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients. Arthritis Res. Ther. 21:77. 10.1186/s13075-019-1860-8", "ArticleIdList": ["10.1186/s13075-019-1860-8", "PMC6425717", "30894219"]}, {"Citation": "Sun H., Chow E. C., Liu S., Du Y., Pang K. S. (2008). The Caco-2 cell monolayer: usefulness and limitations. Expert Opin. Drug Metab. Toxicol. 4 395\u2013411. 10.1517/17425255.4.4.395", "ArticleIdList": ["10.1517/17425255.4.4.395", "18433344"]}, {"Citation": "Szatmari I., Vamosi G., Brazda P., Balint B. L., Benko S., Szeles L., et al. (2006). Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem. 281 23812\u201323823. 10.1074/jbc.M604890200", "ArticleIdList": ["10.1074/jbc.M604890200", "16785230"]}, {"Citation": "To K. K., Tomlinson B. (2013). Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARgamma agonists. Br. J. Pharmacol. 170 1137\u20131151. 10.1111/bph.12367", "ArticleIdList": ["10.1111/bph.12367", "PMC3949660", "24032744"]}, {"Citation": "Veerapur V. P., Prabhakar K. R., Thippeswamy B. S., Bansal P., Srinivasan K. K., Unnikrishnan M. K. (2012). Antidiabetic effect of Ficus racemosa Linn. stem bark in high-fat diet and low-dose streptozotocin-induced type 2 diabetic rats: a mechanistic study. Food Chem. 132 186\u2013193. 10.1016/j.foodchem.2011.10.052", "ArticleIdList": ["10.1016/j.foodchem.2011.10.052", "26434279"]}, {"Citation": "Wang J., Zhu X. X., Liu L., Xue Y., Yang X., Zou H. J. (2016). SIRT1 prevents hyperuricemia via the PGC-1alpha/PPARgamma-ABCG2 pathway. Endocrine 53 443\u2013452. 10.1007/s12020-016-0896-7", "ArticleIdList": ["10.1007/s12020-016-0896-7", "27022940"]}, {"Citation": "Wang K., Li Y. F., Lv Q., Li X. M., Dai Y., Wei Z. F. (2017). Bergenin, acting as an agonist of PPARgamma, ameliorates experimental colitis in mice through improving expression of SIRT1, and therefore inhibiting NF-kappaB-mediated macrophage activation. Front. Pharmacol. 8:981. 10.3389/fphar.2017.00981", "ArticleIdList": ["10.3389/fphar.2017.00981", "PMC5770370", "29375382"]}, {"Citation": "Ye C., Hou W., Chen M., Lu J., Chen E., Tang L., et al. (2019). IGFBP7 acts as a negative regulator of RANKL-induced osteoclastogenesis and oestrogen deficiency-induced bone loss. Cell Prolif. 53:e12752. 10.1111/cpr.12752", "ArticleIdList": ["10.1111/cpr.12752", "PMC7046308", "31889368"]}, {"Citation": "Yoon I.-S., Park D.-H., Ki S.-H., Cho S.-S. (2016). Effects of extracts fromCorylopsis coreanaUyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia. J. Pharm. Pharmacol. 12 1597\u20131603. 10.1111/jphp.12626", "ArticleIdList": ["10.1111/jphp.12626", "27696407"]}]}], "History": [{"Year": "2020", "Month": "5", "Day": "4"}, {"Year": "2020", "Month": "7", "Day": "10"}, {"Year": "2020", "Month": "8", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "28", "Hour": "6", "Minute": "1"}, {"Year": "2020", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["32850823", "PMC7403512", "10.3389/fcell.2020.00703"]}}]}